Cronos Group (CRON) Receives Daily Media Sentiment Rating of 0.28
Media coverage about Cronos Group (NASDAQ:CRON) has been trending positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cronos Group earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.4401770156474 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s analysis:
- Israel’s Infant Cannabis Industry at Risk as Government Waffles on Allowing Exports (haaretz.com)
- Cronos Group, First Cannabis Company to Trade on the NASDAQ Prepares for Growth as a Leader in the Legal Cannabis Sector (finance.yahoo.com)
- An Eye on Trend-Spotting Tool – Cronos Group Inc. (NASDAQ: CRON) (financerater.com)
- Notable Stocks in the News: Cronos Group Inc., (NASDAQ: CRON), Iovance Biotherapeutics, Inc., (NASDAQ: IOVA) (globalexportlines.com)
- Cronos Group Inc (CRON) Short Interest Up 35.0% in May (americanbankingnews.com)
A number of research firms recently issued reports on CRON. Canaccord Genuity lowered Cronos Group from a “hold” rating to a “sell” rating in a report on Tuesday, May 1st. GMP Securities upgraded Cronos Group from a “hold” rating to a “buy” rating in a report on Friday, April 6th. Finally, Beacon Securities restated a “buy” rating on shares of Cronos Group in a research note on Friday, May 4th.
Cronos Group (NASDAQ:CRON) last posted its quarterly earnings results on Monday, April 30th. The company reported $0.01 earnings per share for the quarter. Cronos Group had a return on equity of 2.74% and a net margin of 35.12%. The company had revenue of $1.27 million for the quarter. research analysts expect that Cronos Group will post -0.01 earnings per share for the current fiscal year.
About Cronos Group
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.